Skip to main content
SpringerLink
Log in

Newer Immunosuppression and Strategies on the Horizon in Heart Transplantation

  • Thoracic Transplantation (J Kobashigawa, Section Editor)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Balanced immunosuppressive therapy is the key to long-term survival after allograft transplantation. With a worldwide median recipient/graft survival of more than 11 years, heart transplantation is a highly successful treatment for selected patients with end-stage heart failure. However, current immunosuppressive regimens are associated with adverse effects. In the balance between acute rejection, cardiac allograft vasculopathy, infections and an increased risk of malignancy, there is room for improvement. The aim of this review article is to present an overview of immunosuppressive mechanisms and new immune therapy strategies in heart transplantation and to highlight emerging approaches in this field that may influence our immunosuppressive strategies in the future.

Recent Findings

Calcineurin inhibitors have been the central drug class in post-transplant immunosuppressive regimens. New trials have explored alternative drugs, such as inhibitors of mechanistic target of rapamycin and belatacept. There is ongoing research on the development of strategies to induce long-term allograft tolerance.

Summary

This review briefly introduces allograft rejection immunology, and sums up contemporary immunosuppressive strategies with emphasis on the development of calcineurin inhibitor-sparing regimens and the prospect of achieving long-term tolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Calne RY, White DJ, Rolles K, Smith DP, Herbertson BM. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet. 1978;1:1183–5.

    Article  CAS  PubMed  Google Scholar 

  2. DiBardino DJ. The history and development of cardiac transplantation. Tex Heart Inst J. 1999;26:198–205.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Gude E, Simonsen S, Geiran OR, Fiane AE, Gullestad L, Arora S, et al. Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. J Heart Lung Transplant. 2010;29:216–23.

    Article  PubMed  Google Scholar 

  4. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report—2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34:1244–54.

    Article  PubMed  Google Scholar 

  5. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation report—2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1158–69.

    Article  PubMed  Google Scholar 

  6. Tallaj JA, Pamboukian SV, George JF, Kirklin JK, Brown RN, McGiffin DC, et al. Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study. J Heart Lung Transplant. 2014;33:1304–11.

    Article  PubMed  Google Scholar 

  7. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. J Heart Lung Transplant. 2013;32:951–64.

    Article  PubMed  Google Scholar 

  8. Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A. 1976;73:3628–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vettermann C, Schlissel MS. Allelic exclusion of immunoglobulin genes: models and mechanisms. Immunol Rev. 2010;237:22–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003;21:139–76.

    Article  CAS  PubMed  Google Scholar 

  11. Hinterberger M, Aichinger M, Prazeres da Costa O, Voehringer D, Hoffmann R, Klein L. Autonomous role of medullary thymic epithelial cells in central CD4(+) T cell tolerance. Nat Immunol. 2010;11:512–9.

    Article  CAS  PubMed  Google Scholar 

  12. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 2000;18:275–308.

    Article  CAS  PubMed  Google Scholar 

  13. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature. 1992;357:375–9.

    Article  CAS  PubMed  Google Scholar 

  14. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–58.

    Article  CAS  PubMed  Google Scholar 

  15. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354:1166–76.

    Article  CAS  PubMed  Google Scholar 

  16. Pelanda R, Torres RM. Central B-cell tolerance: where selection begins. Cold Spring Harb Perspect Biol. 2012;4:a007146.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15:185–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 2004;18:1–11.

    Article  PubMed  Google Scholar 

  19. Stavnezer J, Amemiya CT. Evolution of isotype switching. Semin Immunol. 2004;16:257–75.

    Article  CAS  PubMed  Google Scholar 

  20. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15:149–59.

    Article  CAS  PubMed  Google Scholar 

  21. • Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131:1608–39. This scientific statement is a thorough review of the mechanisms behind antibody-mediated rejection in heart transplant recipients and current treatment options.

    Article  PubMed  Google Scholar 

  22. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–16.

    Article  CAS  PubMed  Google Scholar 

  23. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.

    Article  CAS  PubMed  Google Scholar 

  24. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87.

    Article  CAS  PubMed  Google Scholar 

  25. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969–80.

    Article  CAS  PubMed  Google Scholar 

  26. Thomson AW. Tolerogenic dendritic cells: all present and correct? Am J Transplant. 2010;10:214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Popow I, Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger GJ, Kundi M, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant. 2013;13:3103–13.

    Article  CAS  PubMed  Google Scholar 

  28. Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G, et al. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. Clin Transpl. 2015;29:9–17.

    Article  CAS  Google Scholar 

  29. Ansari D, Lund LH, Stehlik J, Andersson B, Hoglund P, Edwards L, et al. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant. 2015;34:1283–91.

    Article  PubMed  Google Scholar 

  30. Azarbal B, Cheng R, Vanichsarn C, Patel JK, Czer LS, Chang DH, et al. Induction therapy with antithymocyte globulin in patients undergoing cardiac transplantation is associated with decreased coronary plaque progression as assessed by intravascular ultrasound. Circ Heart Fail. 2016;9:e002252.

    CAS  PubMed  Google Scholar 

  31. Mangiola M, Marrari M, Feingold B, Zeevi A. Significance of anti-HLA antibodies on adult and pediatric heart allograft outcomes. Front Immunol. 2017;8:4.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cole RM, Kobashigawa JA. Desensitization strategies pre- and post-cardiac transplantation. Curr Treat Options Cardiovasc Med. 2016;18:8.

    Article  PubMed  Google Scholar 

  33. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transpl. 2011;25:E61–7.

    Article  Google Scholar 

  34. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30:1320–6.

    Article  PubMed  Google Scholar 

  35. Reinsmoen NL, Patel J, Mirocha J, Lai CH, Naim M, Ong G, et al. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. J Heart Lung Transplant. 2016;35:165–72.

    Article  PubMed  Google Scholar 

  36. Sarwal MM. Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization. Clin Biochem. 2016;49:404–10.

    Article  CAS  PubMed  Google Scholar 

  37. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.

    Article  PubMed  Google Scholar 

  38. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890–900.

    Article  CAS  PubMed  Google Scholar 

  39. Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation-05 study. Am J Transplant. 2016;16:121–36.

    Article  CAS  PubMed  Google Scholar 

  40. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69.

    Article  PubMed  Google Scholar 

  41. Kfoury AG, Renlund DG, Snow GL, Stehlik J, Folsom JW, Fisher PW, et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant. 2009;28:51–7.

    Article  PubMed  Google Scholar 

  42. Singh N, Vanlandingham S, Halverson C, Marques MB, Tallaj J, Kirklin J, et al. Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody-mediated rejection. J Clin Apher. 2014;29:316–21.

    Article  PubMed  Google Scholar 

  43. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24:1337–42.

    Article  PubMed  Google Scholar 

  44. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation. 2005;79:1121–7.

    Article  CAS  PubMed  Google Scholar 

  45. Thomas KA, Valenzuela NM, Gjertson D, Mulder A, Fishbein MC, Parry GC, et al. An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA. Am J Transplant. 2015;15:2037–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003;17:2205–32.

    Article  CAS  PubMed  Google Scholar 

  47. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336–45.

    Article  CAS  PubMed  Google Scholar 

  48. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, Yacoub M, et al. European multicenter tacrolimus (FK506) heart pilot study: one-year results—European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 1998;17:775–81.

    CAS  PubMed  Google Scholar 

  49. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizon Del Prado JM, Pulpon LA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients—a large European trial. Am J Transplant. 2006;6:1387–97.

    Article  CAS  PubMed  Google Scholar 

  50. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377–86.

    Article  CAS  PubMed  Google Scholar 

  51. Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. Transplantation. 2013;95:629–34.

    Article  CAS  PubMed  Google Scholar 

  52. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant. 2004;23:S202–6.

    Article  PubMed  Google Scholar 

  53. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39–68.

    Article  CAS  PubMed  Google Scholar 

  54. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379–84.

    Article  CAS  PubMed  Google Scholar 

  55. Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ, et al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J. 2008;29:2742–50.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664–70.

    Article  CAS  PubMed  Google Scholar 

  57. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–58.

    Article  CAS  PubMed  Google Scholar 

  58. Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13:1203–16.

    Article  CAS  PubMed  Google Scholar 

  59. Lehmkuhl HB, Arizon J, Vigano M, Almenar L, Gerosa G, Maccherini M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009;88:115–22.

    Article  CAS  PubMed  Google Scholar 

  60. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010;89:864–72.

    Article  CAS  PubMed  Google Scholar 

  61. Zuckermann A, Wang SS, Ross H, Frigerio M, Eisen HJ, Bara C, et al. Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: a multicentre, randomized trial. J Transplant. 2011;2011:535983.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Cornu C, Dufays C, Gaillard S, Gueyffier F, Redonnet M, Sebbag L, et al. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;78:24–32.

    Article  CAS  PubMed  Google Scholar 

  63. Gude E, Gullestad L, Andreassen AK. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all? Curr Opin Organ Transplant. 2017;22:198–206.

  64. • Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014;14:1828–38. This randomized controlled trial showed that an early switch from cyclosporine to everolimus provides renoprotection in de novo heart transplant recipients.

    Article  CAS  PubMed  Google Scholar 

  65. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study. Am J Transplant. 2016;16:1238–47.

    Article  CAS  PubMed  Google Scholar 

  66. Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Botker HE, et al. The effect of Everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo recipients: one-year results of a Scandinavian randomized trial. Am J Transplant. 2015;15:1967–75.

    Article  CAS  PubMed  Google Scholar 

  67. Hunt JB, Starling RC, Rabágo G, Banner NR, Kobashigawa J, Keogh A, et al. Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant. 2007;26:S203.

  68. Qiu Y, Wang X, Fan J, Rao Z, Lu Y, Lin T. Conversion from calcineurin inhibitors to mammalian target-of-rapamycin inhibitors in heart transplant recipients: a meta-analysis of randomized controlled trials. Transplant Proc. 2015;47:2952–6.

    Article  CAS  PubMed  Google Scholar 

  69. Deuse T, Bara C, Barten MJ, Hirt SW, Doesch AO, Knosalla C, et al. The MANDELA study: a multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation. Contemp Clin Trials. 2015;45:356–63.

    Article  PubMed  Google Scholar 

  70. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–53.

    Article  CAS  PubMed  Google Scholar 

  71. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.

    Article  CAS  PubMed  Google Scholar 

  72. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547–57.

    Article  CAS  PubMed  Google Scholar 

  73. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12:554–62.

    Article  CAS  PubMed  Google Scholar 

  74. • Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–43. This trial confirmed the feasibility of non-calcineurin inhibitor-based therapy in solid organ transplantation.

    Article  CAS  PubMed  Google Scholar 

  75. Durrbach A, Pestana JM, Florman S, Del Carmen RM, Rostaing L, Kuypers D, et al. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. 2016;16:3192–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. • Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817–27. This trial illustrates that results regarding immunosuppressive therapy are organ specific and cannot necessarily be extrapolated to other organs.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Madariaga ML, Kreisel D, Madsen JC. Organ-specific differences in achieving tolerance. Curr Opin Organ Transplant. 2015;20:392–9.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Zhang Z, Zhu L, Quan D, Garcia B, Ozcay N, Duff J, et al. Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation. 1996;62:1267–72.

    Article  CAS  PubMed  Google Scholar 

  79. •• Kawai T, Sachs DH, Sykes M, Cosimi AB. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2013;368:1850–2. This proof-of-concept trial showed that induction of tolerance is achievable in solid organ transplant recipients.

  80. Leventhal JR, Elliott MJ, Yolcu ES, Bozulic LD, Tollerud DJ, Mathew JM, et al. Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation. 2015;99:288–98.

    Article  CAS  PubMed  Google Scholar 

  81. Kawai T, Cosimi AB, Wee SL, Houser S, Andrews D, Sogawa H, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation. 2002;73:1757–64.

    Article  CAS  PubMed  Google Scholar 

  82. Gorantla VS, Schneeberger S, Brandacher G, Sucher R, Zhang D, Lee WP, et al. T regulatory cells and transplantation tolerance. Transplant Rev. 2010;24:147–59.

    Article  Google Scholar 

  83. Boardman D, Maher J, Lechler R, Smyth L, Lombardi G. Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy? Biochem Soc Trans. 2016;44:342–8.

    Article  CAS  PubMed  Google Scholar 

  84. Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest. 2008;118:3619–28.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Hall BM, Tran G, Hodgkinson SJ. Alloantigen specific T regulatory cells in transplant tolerance. Int Immunopharmacol. 2009;9:570–4.

    Article  CAS  PubMed  Google Scholar 

  86. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3:83ra42.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Noyan F, Zimmermann K, Hardtke-Wolenski M, Knoefel A, Schulde E, Geffers R, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am J Transplant. 2016;17:917–30.

    Article  Google Scholar 

  88. Landwehr-Kenzel S, Issa F, Luu SH, Schmuck M, Lei H, Zobel A, et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am J Transplant. 2014;14:594–606.

    Article  CAS  PubMed  Google Scholar 

  89. Yates SF, Paterson AM, Nolan KF, Cobbold SP, Saunders NJ, Waldmann H, et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol. 2007;179:967–76.

    Article  CAS  PubMed  Google Scholar 

  90. Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, Ding R, et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104:2821–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Kleist C, Sandra-Petrescu F, Jiga L, Dittmar L, Mohr E, Greil J, et al. Generation of suppressive blood cells for control of allograft rejection. Clin Sci. 2015;128:593–607.

    Article  CAS  PubMed  Google Scholar 

  92. Komarowska I, Coe D, Wang G, Haas R, Mauro C, Kishore M, et al. Hepatocyte growth factor receptor c-met instructs T cell cardiotropism and promotes T cell migration to the heart via autocrine chemokine release. Immunity. 2015;42:1087–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Postboks 4950, Nydalen, 0424, Oslo, Norway

    Kaspar Broch, Einar Gude, Arne K. Andreassen & Lars Gullestad

  2. Faculty of Medicine, University of Oslo, Oslo, Norway

    Arne K. Andreassen & Lars Gullestad

Authors
  1. Kaspar Broch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Einar Gude
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arne K. Andreassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lars Gullestad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaspar Broch.

Ethics declarations

Conflict of Interest

Arene Andreassen, Einar Gude, Lars Gullestad, and Kaspar Broch declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Thoracic Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Broch, K., Gude, E., Andreassen, A.K. et al. Newer Immunosuppression and Strategies on the Horizon in Heart Transplantation. Curr Transpl Rep 4, 226–237 (2017). https://doi.org/10.1007/s40472-017-0159-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-017-0159-4

Keywords

Search

Navigation